Prevnar13

Manufactured by Pfizer

Sourced in United States

Prevnar13 is a pneumococcal conjugate vaccine developed by Pfizer. It is designed to protect against 13 serotypes of Streptococcus pneumoniae bacteria, which can cause various pneumococcal diseases. The vaccine is formulated as a suspension for intramuscular injection.

Automatically generated - may contain errors

Lab products found in correlation

Pneumovax, by Merck Group (4 mentions) Aluminum phosphate, by Brenntag (3 mentions) Phid cv, by GlaxoSmithKline (2 mentions) Np klh, by Biosearch Technologies (2 mentions) Pcv13, by Pfizer (1 mentions) C57bl 6ncr mice, by Charles River Laboratories (1 mentions) Phosphate buffered saline (pbs), by Thermo Fisher Scientific (1 mentions) Polysaccharides, by Merck Group (1 mentions) Ll 37, by InvivoGen (1 mentions) Dogs nta ni, by Avanti Polar Lipids (1 mentions) Fluzone, by Sanofi (1 mentions) Energix b, by GlaxoSmithKline (1 mentions) Aluminum hydroxide, by Merck Group (1 mentions) Infanrix ipv hib, by GlaxoSmithKline (1 mentions) Synflorix, by GlaxoSmithKline (1 mentions) Havrix, by GlaxoSmithKline (1 mentions)

24 protocols using prevnar13

Nasopharyngeal & Saliva Sampling in Pneumococcal-Vaccinated Children

Cited 4 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

In the Netherlands, nasopharyngeal and saliva samples were collected from n = 653 children vaccinated with 10 valent pneumococcal conjugated vaccine (PHiD-CV, GlaxoSmithKline), including n = 327 24-month-old vaccinated with PHiD-CV according to “2 primary + 1 booster” dose schedule and n = 326 children aged 44–49 months (“4-year-old”) vaccinated following a “3 primary + 1 booster” schedule. In addition, nasopharyngeal, oropharyngeal, and saliva samples were collected from n = 318 parents of 24-month-old (“2-year-old”, one parent per child). In England, nasopharyngeal swabs were collected from n = 293 children aged 1–5 years vaccinated with 13-valent conjugated polysaccharide vaccine (Prevnar-13, Pfizer) in a “2 primary +1 booster” dose schedule and from n = 284 adult household contacts of the children [16 (link)].
Nasopharyngeal and oropharyngeal swabs were collected and processed in accordance with the protocol recommended by the World Health Organization [17 (link)]. Procedures for collection of samples in The Netherlands [7 (link), 9 (link), 15 (link)] and in England [16 (link)] are detailed in supplementary materials.

Miellet W.R., Mariman R., van Veldhuizen J., Badoux P., Wijmenga-Monsuur A.J., Litt D., Bosch T., Miller E., Fry N.K., van Houten M.A., Rots N.Y., Sanders E.A, & Trzciński K. (2024). Impact of age on pneumococcal colonization of the nasopharynx and oral cavity: an ecological perspective. ISME Communications, 4(1), ycae002.

+ Open protocol

+ Expand

Immune Response to PCV13 in Dialysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

All patients received a single dose of PCV13 (Prevnar13, Pfizer, lots: H22520, J77978, M573833, M73833, R56653, and T24279) administered intramuscularly in the deltoid region during the dialysis procedure. Ten milliliters of peripheral blood for B-cell analysis were collected into BD Vacutainer™ tubes with sodium heparin (BD Biosciences, Baltimore, MD, USA) immediately prior to immunization for flow cytometry analysis and 7 days post-immunization for flow cytometry and ELISPOT. Blood was collected for complete blood counts (CBC) just before immunization and day 7 post-immunization. An additional 10 mL of peripheral blood for serum antibody analysis was collected into BD Vacutainer™ Venous Blood Collection Tubes: SST™ Serum Separation Tubes: Hemogard (BD Biosciences) pre- and 28 days post-immunization, serum was stored at − 80 °C.

Gaultier G.N., McCready W, & Ulanova M. (2019). The effect of pneumococcal immunization on total and antigen-specific B cells in patients with severe chronic kidney disease. BMC Immunology, 20, 41.

+ Open protocol

+ Expand

Heligmosomoides polygyrus infection and influenza challenge protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Animals were infected by gavage with 200 third stage larvae of Heligmosomoides polygyrus as described^{10 (link)}. In some experiments, adult Hp parasites were eliminated by two oral administrations of 100 mg/kg pyrantel pamoate (Columbia Laboratories, Ottawa, Ontario) delivered 2 d apart. For heterologous challenge experiments, some mice were immunized in the footpad with 100μg of NP-KLH (Biosearch technologies) precipitated in alum (Imject 77161, ThermoScientific) or intramuscularly with 0.5μg Prevnar13^® (Pfizer). Influenza infections were performed intranasally with a sublethal dose (50 PFU) of H1N1 strain A/Puerto Rico/8/34 in a 25μl volume. Virus was propagated and isolated from Madin-Darby canine kidney (MDCK) cells and titrated with standard plaque assay in MDCK cells^{23 (link)}.

King I.L., Mohrs K., Meli A.P., Downey J., Lanthier P., Tzelepis F., Fritz J.H., Tumanov A.V., Divangahi M., Leadbetter E.A, & Mohrs M. (2017). Intestinal helminth infection impacts the systemic distribution and function of the naïve lymphocyte pool. Mucosal immunology, 10(5), 1160-1168.

+ Open protocol

+ Expand

Heligmosomoides polygyrus infection and influenza challenge protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

+ Open protocol

+ Expand

Prevnar13 Vaccine Response in Healthy Donors

Check if the same lab product or an alternative is used in the 5 most similar protocols

Nine healthy donors were recruited by the Immunodeficiency Unit at Karolinska University Hospital Huddinge (44 (link)). Serum were collected from these donors before vaccination and at week 2 or 4 after vaccination with Prevnar13 (Pfizer), and data on specific serum IgG titers and opsonophagocytic activity (OPA) collected as described (44 (link)). The study was performed in accordance with the Declaration of Helsinki and approved by the Regional Ethics Review Board in Stockholm and by the Swedish Medical Product Agency. The study was registered at www.clinicaltrials.gov as NCT01847781. Written consent was obtained from all subjects prior to inclusion.

Boulouis C., Gorin J.B., Dias J., Bergman P., Leeansyah E, & Sandberg J.K. (2020). Opsonization-Enhanced Antigen Presentation by MR1 Activates Rapid Polyfunctional MAIT Cell Responses Acting as an Effector Arm of Humoral Antibacterial Immunity. The Journal of Immunology Author Choice, 205(1), 67-77.

+ Open protocol

+ Expand

Pneumococcal Vaccination in Botswana

Check if the same lab product or an alternative is used in the 5 most similar protocols

Botswana is a landlocked country in southern Africa with a semi-arid climate and a short rainy season that typically occurs from November to March. The country’s under-five child mortality rate was estimated to be 41.6 per 1,000 live births in 2019 [18 ]. Gaborone, the capital and largest city in Botswana, is located in the country’s South-East district and was estimated to have a population of 231,626 in 2011 [19 ]. In July 2012, 13-valent pneumococcal conjugate vaccine (Prevnar 13^®, Pfizer; PCV-13) was included in the national immunization program as a 3-dose primary series without a booster (3+0 schedule) with doses administered at 2, 3, and 4 months of age. There was no national program for vaccination of adults or pregnant women against pneumococcus during the study period. The HIV prevalence among individuals 15 to 49 years of age in Botswana was 20.7% in 2019 [20 ]. More than 95% of pregnant women with HIV in Botswana receive antiretroviral therapy, and the vertical HIV transmission rate is estimated to be less than 2% [20 ].

Uffman E.A., Li S.H., Chen J.L., Allen N., Boiditswe S., Fouda G.G., Hurst J.H., Patel M.Z., Steenhoff A.P., Cunningham C.K., Qin E., Davenport C.A, & Kelly M.S. (2022). Kinetics of pneumococcal antibodies among HIV-exposed, uninfected infants in Botswana. Vaccine, 40(33), 4764-4771.

+ Open protocol

+ Expand

Pneumococcal Vaccine Immunization in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

Specific Pathogen Free, 8-week-old female C57BL/6Ncr mice were purchased from Charles River Laboratories (Wilmington, MA, USA). To induce anti-Streptococcus pneumoniae immunity, mice were vaccinated intramuscularly (i.m.) either with 3 μg of Pneumococcal surface protein A (family 1 Clade 2) plus 0.2 mg of aluminum hydroxide, 3 μg of Prevnar13 (Pfizer, New York, NY, USA), or PBS (Life Technologies, Carlsbad, CA, USA) given in a 100 μL volume. Mice were boosted 3 weeks post-prime and bled at week 4 for antibody quantification. Mice were housed within the Animal Research Facility of Albany Medical College. All experimental procedures were approved by the Institutional Animal Use and Care Committee (Protocol Number 17-03006). The following reagent was obtained through BEI Resources, NIAID, NIH: Streptococcus pneumoniae Family 1, Clade 2 Pneumococcal Surface Protein A (PspA UAB055) with C-Terminal Histidine Tag, Recombinant from Escherichia coli, NR-33178.

Roberts S., Williams C.M., Salmon S.L., Bonin J.L., Metzger D.W, & Furuya Y. (2019). Evaluation of Pneumococcal Surface Protein A as a Vaccine Antigen against Secondary Streptococcus pneumoniae Challenge during Influenza A Infection. Vaccines, 7(4), 146.

+ Open protocol

+ Expand

Bacterial and Cell Culture Media

Check if the same lab product or an alternative is used in the 5 most similar protocols

Bacterial and cell culture media [including chemically defined bacterial growth medium (CDM)] and reagents were purchased from Fisher Chemical and Sigma-Aldrich. Sheep blood was purchased from Hemostat Laboratories. Lipids DOPG-Na and DSPE-PEG2000 were obtained from NOF. DOGS-NTA-Ni was purchased from Avanti Polar Lipids. Dioleoylphosphatidylcholine (DOPC), cholesterol, alum (as aluminum phosphate), and polysaccharides were purchased from Sigma-Aldrich. LL-37 was purchased from InvivoGen. Prevnar 7 and Prevnar 13 and Pneumovax 23 vaccines were obtained from Pfizer and Merck, respectively.

Jones C.H., Zhang G., Nayerhoda R., Beitelshees M., Hill A., Rostami P., Li Y., Davidson B.A., Knight P I.I.I, & Pfeifer B.A. (2017). Comprehensive vaccine design for commensal disease progression. Science Advances, 3(10), e1701797.

+ Open protocol

+ Expand

Multivalent Pneumococcal Polysaccharide Conjugate

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 7

Pneumococcal polysaccharide-CRM197 covalent. Compounds for serotypes containing 1, 3, 5, 7F, 14, 18C, 22F, 23F, 33F, 35B (10 serotypes polysaccharides) and cross-reactive polysaccharide compounds of (6A, 6B), (9V, 9N), (15A, 15B) and (19A, 19F) (8 serotypes) were combined to yield final polysaccharide concentration of 2.2-4.4 μg PS/mL (1.1-2.2 μg/human dose, 0.5 mL). Sodium chloride (150 mM) solution, 10-20 mM histidine, 20 mM HEPES or MOPS buffer and 0.001% Tween-20 was also used during the formulation process as diluent, and aluminum phosphate (Adju-Phos, Brenntag, USA) was used as investigational adjuvant.

18-valent or higher valent (>20V-24V) covalent compound was aseptically filled in 2 mL sterile vials. PNEUMOVAX® (Merck, USA) and/or PREVNAR-13® (Pfizer, USA) were used as controls.

US11376323B2. Mixtures of polysaccharide protein pegylated compounds (2022-07-05). Inventprise, LLC [US]. Inventors: Subhash V. Kapre [US], Anup K. Datta [US].

+ Open protocol

+ Expand

Maternal Pneumococcal Vaccine Immunity

Check if the same lab product or an alternative is used in the 5 most similar protocols

Adult, female mice were vaccinated with PCV13 (Prevnar13; Pfizer) by intramuscular injection (50 μl), two times at an interval of 21 days (28 (link)). Control mice received PBS. The mice were then bred, and pups were utilized in experiments. The presence of anti-pneumococcal capsule IgG in serum of mothers and their pups was confirmed by polysaccharide ELISA.

Zangari T., Wang Y, & Weiser J.N. (2017). Streptococcus pneumoniae Transmission Is Blocked by Type-Specific Immunity in an Infant Mouse Model. mBio, 8(2), e00188-17.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!